Lenzing's Surgical Strike: Profit Rises as the Fibre Maker Cuts Deep to Reshape Itself

Lenzing's H1 net profit doubles to €35.6M despite revenue dip, as it pivots to nonwovens and cuts 2,000 jobs in a €600M restructuring.

The numbers landing on Lenzing's half-year report card tell a story that at first glance looks contradictory. Net profit more than doubled to €35.6 million from €15.2 million a year earlier, yet revenue slipped from €1.34 billion to roughly €1.27 billion. The explanation is less a paradox than a preview of where the Austrian fibre specialist is steering the business: away from volume, toward margin.

That strategic pivot was formalised in late July under the banner "Grow Nonwovens, Reset Textiles," a restructuring programme that carries real human and financial costs. Around 2,000 jobs are slated to go by the end of 2027 — with 600 of those cuts in administration already confirmed — as Lenzing winds down fibre production at its Heiligenkreuz site in Austria by end-2026 and its Grimsby facility in the UK by end-2027. Both plants are being put up for sale. The human toll is concentrated: 285 employees in Heiligenkreuz and 215 in Grimsby are affected, and Burgenland's governor Hans Peter Doskozil has signalled he would not rule out a state takeover of the site.

A Margin Story With a Caveat

The headline profit jump needs context. EBITDA actually fell to €239.2 million from €268.6 million in the prior-year period, pulling the EBITDA margin down from 20.0 percent to 18.9 percent. The company attributes the revenue decline to lower fibre sales volumes and prices, plus weaker pulp prices — partly a deliberate consequence of exiting low-margin standard fibres. That explains why the bottom line improved even as the top line shrank: the mix is better, even if the engine is smaller.

The one figure that offers genuine reassurance is free cash flow, which ticked up to €45.8 million from €43.1 million. In a phase where the balance sheet is being stretched by transformation costs, cash generation matters more than accounting profit.

Those costs are substantial. Impairments for 2026 could reach €150 million, with restructuring provisions of up to €40 million on top. This is not a routine cost-cutting exercise; it is a strategic retreat from a structurally unprofitable business segment.

The Portfolio Reshuffle

Lenzing's target is to reduce textiles from 45 percent of the portfolio to roughly 30 percent over the medium term, while nonwovens and pulp each grow to around 30 percent. The logic is industrial rather than sentimental: hygiene products, wet wipes and filtration carry more stable margins than standard textiles, a segment plagued by overcapacity.

The transformation is being financed with a €600 million package, of which up to €300 million comes from a rights issue. The extraordinary general meeting to approve it takes place on August 25. Anchor shareholders B&C Group and Suzano have already committed up to €156.7 million combined, with Oberbank adding around €11.6 million — a show of faith that materially de-risks the deal.

Where the Share Price Sits

The market's verdict remains mixed. The stock trades near €23.50, roughly 21 percent below its 52-week high of €29.75 reached in June, yet about 21 percent above the March low of €19.40. Since the capital increase was announced roughly two weeks ago, the shares have recovered about 2.0 percent — modest evidence that investors appreciate the balance-sheet stabilisation, even as they weigh the dilution that comes with it.

With a market capitalisation of €915.25 million, Lenzing remains just shy of the billion-euro mark. The central question for shareholders is whether the improved operating margin and positive cash flow prove durable while plants are shuttered and headcount shrinks. The half-year report offers an encouraging first signal: despite lower revenue, the company is earning considerably more than it did a year ago.

The coming weeks around the extraordinary general meeting will test whether the market believes the turnaround story with the same conviction as the company's largest owners. For patient investors, the prize is a leaner, higher-margin Lenzing on the other side of the operation. For those seeking a quick recovery, the near-term arithmetic — restructuring charges, dilution, plant closures — argues for caution.